Literature DB >> 33408492

Discrimination of Chronic Kidney Disease and Diabetic Nephropathy and Analysis of Their Related Influencing Factors.

Xiumin Liu1, Yinpei Guo2, Jing Wu1, Nan Yao2, Han Wang2, Bo Li2.   

Abstract

PURPOSE: Clinically there are not many clinical indicators to differentiate diabetic kidney disease (DKD) and chronic kidney disease (CKD). Data from laboratory inspections on admission of clinical patients were used to complete the relationship and discrimination analysis of the two diseases. PATIENTS AND METHODS: All subjects were taken from the Department of Nephrology of the Second Hospital of Jilin University from January 2019 to September 2020 with clinical diagnosis of CKD or diabetic nephropathy and no other diseases. After querying the hospital's medical record system, the basic demographic information was obtained, and data on cardiovascular, metabolism, renal function, blood function, and other relevant indicators were extracted as well. IBM SPSS 24.0 software was used for data collation and analysis.
RESULTS: A total of 1726 inpatients (986 males and 740 females) over 18 years old were included, 1407 were CKD patients, 319 were DKD patients. Female accounted for 55.4% in CKD patients, 64.6% in DKD patients. Compared to men, women may be more susceptible to DKD (OR=2.234). DKD patients were more likely to be have higher DP, GLU, eGFR, TCHO, and abnormal TVU (OR=1.746, 3.404, 1.107, 3.004, 14.03) while VB12 was the relative risk factor for CKD; thus, low VB12 level is more likely to happen in CKD patients (OR=0.054, OR95%CI: 0.005-0.552, P=0.014) compared with DKD patients. The stepwise discriminant analysis was completed, only 11 of the 34 variables had discriminative significance. The discriminant score (DS) was set to explore its test efficiency of DKD prediction by drawing ROC curve. Discriminant formula used for CKD and DN identification was given in the study.
CONCLUSION: Female, higher DP, fasting blood GLU and TCHO level seemed to be more indicative for DKD, while lower eGFR level and VB12 deficiency were more likely to point to CKD. Doctors can refer to the discriminant formula to assist in the differential diagnosis of the two diseases after completing the detection of DP, fasting blood GLU, Cys-C, eGFR, TVU, TCHO, FA, VB12, CK, and CK-Mb.
© 2020 Liu et al.

Entities:  

Keywords:  ROC curve; chronic kidney disease; diabetic kidney disease; discriminant analysis; multivariate logistic regression

Year:  2020        PMID: 33408492      PMCID: PMC7779288          DOI: 10.2147/DMSO.S275398

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.168


Plain Language Summary

Clinically there are not enough specific indicators for differentiating diabetic kidney disease (DKD) and chronic kidney disease (CKD) except for blood-glucose-related indicators which can be auxiliary. The prevalence of DKD is increasing significantly, while many patients have already developed symptoms without reaching the traditional standard of more than 10 years of diabetic history. Therefore, our group used the various data of biochemical examination of inpatients from the Department of Nephrology of the Second Affiliated Hospital to make a differential analysis of the two diseases. We found that women are more likely to suffer from DKD, and DP, fasting blood GLU and TCHO seem to be the more indicative indicators for DKD compared to CKD, while worse performances of eGFR and VB12 levels are more likely to point to CKD. We also gave the specific discriminant of both CKD and DKD after stepwise discriminant analysis, including 11 indicators gender, DP, fasting blood GLU, Cys-C, eGFR, TVU, TCHO, FA, VB12, CK, and CK–Mb in it, which can help doctors to identify DKD and CKD more accurately.

Introduction

Nephropathy can damage human health to varying degrees due to changes in kidney function or organ function. According to the developing speed, nephropathy can be divided into chronic kidney disease (CKD) and acute kidney disease. As one of the most common diseases in CKD, diabetic kidney disease (DKD) has the characteristics of high incidence, long duration, hard to heal and easy to progress. There are not many clinical indicators for differentially diagnosing DKD and CKD. Kidney biopsy, as the gold standard for DKD, however, cannot be carried out extensively for its invasive particularity. Thus, traditionally, doctors mostly focus on the patient’s diabetes history to assist diagnosis. Under these circumstances, only patients with a history of diabetes for more than 10 years would be considered having DKD. Besides, doctors could also refer to pathological manifestations or biochemical indicators such as whether there is diabetic retinopathy or abnormal changes in urine protein within the range of kidney disease to complete the diagnosis,1 but these all need certain conditions. Therefore, without a long history of diabetes, no characteristic pathological changes or obvious biochemical indicators to assist diagnosing, the identification ofr DKD is difficult and inefficient. Therefore, it is meaningful to use the various test indicators completed at the time of admission to effectively distinguish DKD patients from patients with different manifestations of CKD.

Homocysteine, Insulin and Folic Acid

Homocysteine (hcy) is an important intermediate produced during methionine and cysteine metabolism.2 The level of hcy in the blood is related to a variety of adverse reactions, which can affect the body's system and cells directly,3 especially damage blood vessels4,5 or cause metabolic diseases.6–9 For patients with kidney disease, the increase of hcy may affect the normal function of vascular endothelial cells and platelets, cause atherosclerosis and thrombosis.10–13 Recent research shows that severe insulin resistance can also lead to elevated homocysteine in the blood.14–16 Serum folic acid (FA) content is also closely related to blood homocysteine level essential for the conversion of homocysteine to methionine.17–19

Blood, Urine Routine and Renal Function Indicators

Abnormalities of white blood cells (WBC), red blood cells (RBC), and hemoglobin (Hb) in routine blood tests may be related to kidney functional damage,20 such as decreased hemoglobin may indicate renal anemia. The clinical significance of activated partial thromboplastin time (APTT) is to detect the lack of endogenous coagulation factors, reduced blood anticoagulant activity may be a red flag for kidney disease.21 The abnormal changes of urine protein, glucose in urine routine represent damage in kidney function, and the elevation of blood urea nitrogen (BUN) not only specifically represents the occurrence of kidney disease, but also may increase the risk of insulin resistance.22,23 However, in the early stages of renal impairment, BUN can be in the normal range. Clinically, the increase in serum creatinine (Scr) indicates damage to renal function as well.24 The level of cysteine protease inhibitor C (Cys-C) is determined by glomerular filtration, not affected by any external factors (gender, age, diet).25 Slightly elevated of Cys-C level may indicate renal insufficiency, but its low level can also happen in early kidney damage.26–28

Cardiovascular Related Indicators

Cardiovascular disease is the leading cause of death in CKD, patients with kidney disease should pay more attention to relevant indicators in long-term treatment and prognosis, such as serum triglycerides (TG), cholesterol (TCHO), low-density lipoprotein (LDL) and high-density lipoprotein (HDL).29,30 In this study, the above indicators were analyzed both among CKD and DKD patients from the department of nephrology in the Second Affiliated Hospital of Jilin University to finish the description of the basic situation, ROC curve for exploring the test efficiency of each factor and discriminant formula writing.

Materials and Methods

Subjects and Data Source

The subjects of this study were taken from the department of nephrology, the Second Affiliated Hospital of Jilin University. All adult inpatients with a clinical diagnosis of CKD or DKD and no other diseases from January 2019 to June 2020 were included, and having received a kidney biopsy to confirm the disease was the inclusion criterion of our study. In particular, patients with specific complications of diabetic nephropathy were excluded, such as diabetic foot, diabetic eye diseases, and other diseases that can be diagnosed intuitively. After excluding subjects with missing information or pregnancy state, 1726 inpatients (986 males and 740 females) over 18 years old were included, among them, 1407 inpatients were CKD patients, 319 inpatients were DKD patients. A total of 34 indicators were included—demographic information was obtained from the hospital’s medical record system. Data of cardiocerebral blood vessels, metabolism, renal function, blood function indicators was extracted based on blood, urine samples, and other clinical examinations at the time of admission to the hospital. The measurement was completed by the Laboratory of the Second Affiliated Hospital of Jilin University, and no subsequent collection and supplementation were performed.

Specific Indicators

The assignment of gender is 1 for male and 2 for female. BMI <18.5 kg/m2 means wasting; BMI between 18.5 and 24.9 kg/m2 means normal; BMI ≥25kg/m2 means overweight; BM1 >30.0 means obesity. Systolic blood pressure (SP) between 90~139 mmHg, diastolic blood pressure (DP) between 60 and approximately 89 mmHg are normal. Normal hcy level is below 15 μmol/L. The normal range of fasting blood glucose (GLU) is 3.89 to approximately 6.1 mmol/L, and 4–6% for glycated hemoglobin (GHb). The normal range of Hb for males is 120–160 g/L, and for females is 110–150 g/L. The RBC normal reference range is 4.5–5.5×1012/L for males, 4.0–5.0×1012/L for females. The normal range of WBC is 4.0–10.0×109/L. The normal platelet count (PLT) for adult ranges from 100–300×109/L. The normal range of adult prothrombin time (PT) is 11.0–13.0 seconds, while exceeding the upper limit of normal for three seconds is abnormal. The normal APTT range is 25.1–35.0 seconds, exceeding the upper limit of the normal reference value for more than 10 seconds has clinical significance. Urine routine tests includes urine protein (urine PRO) and urine glucose (urine GLU) should both be negative under normal circumstances. Renal function related indicators: normal range for BUN is 8–21 mg/dL, for Scr is 44~133 μmol/L, and for Cys-C is 0.54–1.25. The normal value of eGFR is 80–120 mL/min. UACR should be <30 mg/g under normal circumstances. TVU should be between 1000 and 2000 mL. The normal range for TG is 0.56–1.71 mmol/L. TCHO should be less than 5.2 mmol/L. LDL should be lower than 3.12 mmol/L, HDL has the normal range 0.7–2.0 mmol/L. FA is 4.5–34.0 nmol/L in normal status. Serum vitamin B12 (VB12) should be above 150.0 ng/dl. Cardiovascular related indicators: the normal range of serum creatine kinase (CK) is 30–135 U/L, and hybrid creatine kinase isoenzymes (CK–MB) should be lower than 16 U/L. The quantification of troponin I (TnI) should be lower than 0.012 ng/mL. The normal range of myoglobin (Mb) is 19–92 μg/L for men and 12–76 μg/L for women. B-natriuretic peptide (BNP) should be 0–300 pg/mL.

Statistical Analysis

IBM SPSS 24.0 was used for data analysis. X ±SD or M (P25, P75) was used for the description of continuous variable, and t-test or Wilcoxon's rank sum test was used for difference analysis. Chi-squared test was used to analyze the difference distribution of categorical variables. The logistic regression model was used to analyzethe relationship between factors and dependent variable. Stepwise discriminant analysis was used to find the appropriate variables to write the discriminant formula of the two diseases on basis of Wilks’ lambda statistic. In general, the F value was set at Fentry=3.84 and Fremoval=2.71. Then, the ROC curve analysis was used for testing efficiency of the formula and significant variables after stepwise discriminant analysis, α=0.05.

Results

Basic Information

As it shown in Table 1, according to the clinical diagnosis stage, among the 1407 CKD patients, there were 3, 7, 21, 45 and 1331 patients from stage 1 to stage 5. There was no significant difference in the average age of patients with DKD and CKD. In CKD patients, the proportion of females was 55.4%, however, in DKD patients, females accounted for 64.6%, while the gender difference between the two groups was statistically significant (P<0.05). The comparison of BMI value and BMI distribution in two groups showed positive results— among CKD patients, the proportion of normal BMI is 54.4%, higher than that among DKD patients, 36.4% (P<0.05). Pathological indices hcy, PT, BUN, Scr, Cys-C, UACR, CK–MB, TnI, MB, BNP levels of CKD patients are higher that of DKD patients. While SP, DP, FBG, GHb, RBC, PLT, eGFR, TVU, TG, TCHO, LDL, HDL, FA, VB12, CK levels of CKD patients are lower than DKD patients (P<0.05). The comorbidities of the two groups are as follows: among them, SHPT represents secondary hyperparathyroidism and CC represents cardiovascular complications. The distribution difference showed not statistically significant between the two groups.
Table 1

Basic Situation of Research Subjects [X±SD/M (P25, P75)/n (%)]

VariableCKD (n=1407)DKD (n=319)PZ/t/χ2
Stage
 13 (0.2)
 27 (0.5)
 321 (1.5)
 445 (3.2)
 51331 (94.6)
Age58.0 (49.0–68.0)57.2±11.60.323−0.987
Gender0.003*−2.977
 Female780 (55.4)206 (64.6)
 Male627 (44.6)113 (35.4)
BMI (kg/㎡)23.4 (20.7–25.9)25.7 (23.5–27.7)0.000**−9.734
BMI classification0.000**−8.332
 <18.5148 (10.5)9 (2.8)
 18.5~24.9807 (54.4)116 (36.4)
 25.0~29.9364 (25.9)151 (47.3)
 >30.088 (6.3)43 (13.5)
SP (mmHg)140.0 (135.0–150.0)148.0 (140.0–160.0)0.025*−2.246
DP (mmHg)82.0 (80.0–90.0)90.0 (80.0–92.0)0.000**−3.657
Hcy (μmol/L)24.0 (16.0–37.0)20.0 (13.0–23.0)0.000**−8.407
GLU (mmol/L)5.9 (5.0–7.4)7.9 (6.1–9.0)0.000**−10.115
GHb (%)6.4 (4.7–7.2)7.5 (6.5–7.8)0.000**−14.769
Hb (g/L)96.0 (85.0–111.0)111.0 (96.0–130.0)0.000**−10.344
RBC (×1012/L)3.3 (2.8– 3.8)3.8 (3.2–4.4)0.000**−9.074
WBC (×109/L)7.3 (5.9–8.6)7.1 (6.0–8.4)0.800−0.253
PLT (×109/L)209.0 (157.0–262.0)235.0 (190.0–292.0)0.000**−5.810
PT(s)11.3 (10.5–12.0)11.0 (10.5–11.4)0.001**−4.451
APTT(s)32.0 (29.9–34.4)32.3 (30.1–34.2)0.587−0.556
Urine PRO0.000**58.656
 (–)74 (2.4)38 (11.9)
 (+)1373 (97.6)281 (88.1)
Urine GLU0.4360.606
 (–)392 (27.9)82 (25.7)
 (+)1015 (72.1)237 (74.3)
BUN (mg/dL)20.9 (13.2–28.1)9.4 (7.2–14.7)0.000**−16.600
Scr (μmol/L)720.0 (529.0–902.0)172.0 (95.0–291.0)0.000**−23.586
Cys-C5.5±1.62.1(1.4,2.8)0.000**25.032
eGFR (mL/min)7.0 (5.1–9.2)43.2 (32.6–46.1)0.000**−19.569
UACR (mg/g)645.2±127.7621.9 (419.9–692.1)0.000**−11.728
TVU (mL)1498.2±412.91943.3 (1900.0–2149.3)0.000**−19.569
TG (mmol/L)1.6 (1.1–2.3)2.3 (1.5–2.6)0.000**−7.803
TCHO (mmol/L)4.1 (3.4–4.9)5.4 (4.4–6.0)0.000**−12.528
LDL (mmol/L)2.4 (1.9–3.1)3.2 (2.5–3.6)0.000**−10.032
HDL (mmol/L)0.9 (0.7–1.1)1.0 (0.8–1.1)0.000**−4.530
FA (nmol/L)8.3 (6.8–8.6)10.6 (8.7–12.5)0.000**−13.583
VB12 (ng/dL)508.6 (411.0–585.7)568.3 (452.0–589.6)0.000**−9.125
CK (U/L)77.0 (49.0–141.4)120.0 (73.0–203.0)0.000**−8.448
CK–MB (U/L)9.0 (8.0–14.0)4.6 (2.0–11.0)0.000**−11.780
TnI (ng/mL)0.02 (0.01–0.06)0.01 (0.00–0.03)0.000**−11.359
Mb (μg/L)140.6(90.3–220.1)79.7 (42.9–131.6)0.000**−11.914
BNP (pg/mL)393.0 (125.0–746.0)117.0 (45.0–397.3)0.000**−9.749
Comorbidity0.11710.182
 SHPT84 (6.0)27 (8.5)
 CC150 (10.7)30 (9.4)
 Hypertension65 (4.6)24 (7.6)
 Neuropathy39 (2.8)11 (3.4)
 Bronchitis21 (1.5)7 (2.0)
 Others90 (6.4)23 (7.2)
 None958 (68.0)197 (61.9)

Notes: **P<0.01; *P<0.05.

Basic Situation of Research Subjects [X±SD/M (P25, P75)/n (%)] Notes: **P<0.01; *P<0.05.

Multivariate Logistic Regression Results

Taking the above variables which were statistically different into multivariate logistic regression model to explore the risk factors of DKD relative to CKD. The results are shown in Table 2.
Table 2

Multivariate Logistic Regression Results of Factors for DKD

VariableβSEWaldPOR (OR95%CI)
Gender
 Male1
 Female0.8040.2669.1140.003*2.234 (1.326–3.766)
BMI−0.0270.0790.1190.7300.973 (0.834–1.136)
BMI classification
 18.5~24.91
 <18.50.0260.6860.0010.9701.026 (0.267–3.940)
 25.0~29.90.4470.4381.0430.3071.564 (0.663–3.689)
 >30.00.1750.8320.0440.8341.191 (0.233–6.087)
SP
 Normal1
 Low2.5354.3220.3440.55712.622 (0.003–603.86)
 High−0.3250.3340.9460.3310.723 (0.376–1.390)
DP
 Normal1
 Low−1.1481.3470.7260.3940.317 (0.023–4.446)
 High0.5580.2674.3500.037*1.746 (1.034–2.949)
hcy
 Normal1
 High0.2450.2870.7290.3931.277 (0.728–2.241)
GLU
 Normal1
 High1.2250.25523.0380.000**3.404 (2.064–5.614)
GHb
 Normal1
 High−0.2710.3150.7420.3890.763 (0.412–1.413)
Hb
 Normal1
 Low0.1240.3740.1090.7411.132 (0.543–2.357)
RBC
 Normal1
 Low0.4280.4330.9750.3231.534 (0.656–3.586)
PLT
 Normal1
 Low−1.0840.6392.8720.0900.338 (0.097–1.185)
 High−0.2430.3030.6400.4240.785 (0.433–1.421)
PT−0.0950.1080.7780.3780.909 (0.736–1.123)
Urine PRO
 (–)1
 (+)0.0270.4840.0030.9561.027 (0.398–2.652)
BUN
 Normal1
 High−0.5480.3182.9730.0850.578 (0.310–1.078)
Scr
 Normal1
 High0.5470.5411.0220.3121.728 (0.598–4.988)
Cys-C
 Normal–-–-1
 High−0.7290.7360.9810.3220.482 (0.114–2.041)
eGFR0.1020.010103.7360.000**1.107 (1.086–1.129)
UACR––
 Normal1
 High0.4940.8700.3220.5701.638 (0.298–9.014)
TVU
 Normal1
 Low/high2.6410.258104.4700.000**14.030 (8.455–
 Normal1
 High0.1260.2930.1850.6671.134 (0.638–2.016)
TCHO
 Normal1
 High1.1000.4017.5140.006*3.004 (1.368–6.594)
LDL
 Normal1
 High0.2260.3620.3910.5321.254 (0.617–2.548)
HDL
 Normal1
 Low−0.6320.4202.2660.1320.532 (0.234–1.210)
FA
 Normal1
 Low0.1180.6180.0360.8491.125 (0.335–3.774)
VB12
 Normal1
 Low−2.9161.1846.0630.014*0.054 (0.005–0.552)
CK
 Normal1
 High0.5210.2823.4290.0641.684 (0.970–2.924)
CK–Mb
 Normal1
 High−0.2470.3070.6500.4200.781 (0.428–1.425)
TnI
 Normal1
 High−0.5040.3012.8110.0940.604(0.335–1.089)
Mb
 Normal1
 High0.0880.2910.0910.7621.092 (0.618–1.930)
BNP
 Normal1
 High0.1570.3020.2690.6041.170 (0.647–2.116)

Notes: **P<0.01; *P<0.05. Controlled the variable age.

Multivariate Logistic Regression Results of Factors for DKD Notes: **P<0.01; *P<0.05. Controlled the variable age. Compared to men, women may be more susceptible to DKD (OR=2.234, OR95%CI: 1.326–3.776, P=0.003). DKD patients were more likely to have higher DP, GLU, eGFR, TCHO and abnormal TVU, they may be the risk factors for DKD (OR=1.746, 3.404, 1.107, 3.004, 14.03. OR95%CI: 1.034–2.949, 2.064–5.614, 1.086–1.129, 1.368–6.594, 8.455–23.282. P=0.037, 0.000, 0.000, 0.006, 0.000), while VB12 was the relative risk factor for CKD, thus, low VB12 level was more likely to happen in CKD patients (OR=0.054. OR95%CI: 0.005–0.552. P=0.014).

Discriminant for CKD and DKD

The stepwise discriminant analysis was completed using variables with significant difference between the two groups (Table 2). Based on the results, only 11 of the 34 variables had discriminative significance with the Wilks’ lambda=0.390, χ2=1616.494, df=11, and P<0.001. The discriminant score (DS) was set to be used as a new variable to explore its test efficiency of DKD prediction. DS = Gender×0.240 + DP×0.006 + GLU×0.232 - Cys-C×0.208 + eGFR×0.050 + TVU×0.0003 + TCHO×0.139 + FA×0.065 + VB12×0.0004 + CK×0.00029 – CK–Mb×0.013–4.041. According to the results of classification statistics, the success rate of discriminating the research object is as high as 94.1% (Table 3), so the discriminant model has high accuracy. Thus, the discriminant formula for CKD patients can be written as Y = Gender×7.4253 + DP×0.6730 + GLU×7.0761 + Cys-C×4.3697 + eGFR×0.2075 + TVU×0.0069 + TCHO×2.7027 + FA×1.0751 + VB12×0.0089 + CK×0.0005 +CK–Mb × 0.1020–89.0257.
Table 3

Classification Results of Original and Cross-validated Method

ActualPredictedConsistency Raten (%)Misclassification Raten (%)
CKDn (%)DKDn (%)
CKD1350 (95.9)57 (4.1)1625 (94.1)101 (5.9)
DKD44 (13.8)275 (86.2)
Classification Results of Original and Cross-validated Method For DKD patients, Y = Gender×8.1960 + DP×0.6930 + GLU×7.8239 + Cys-C×3.7010 + eGFR×0.3693 + TVU×0.0080 + TCHO×3.1511 + FA×1.2849 + VB12×0.0101 + CK×0.0014 +CK–Mb × 0.0594–105.2924 (Table 4).
Table 4

CKD and DKD Classification Function Coefficients

VariableCKDDKD
Gender7.42538.196
DP0.6730.693
GLU7.07617.8239
Cys-C4.36973.701
eGFR0.20750.3693
TVU0.00690.008
TCHO2.70273.1511
FA1.07511.2849
VB120.00890.0101
CK0.00050.0014
CK–-Mb0.1020.0594
Constant−89.0257−105.292
CKD and DKD Classification Function Coefficients

ROC Curve of Indicators

Eleven variables which showed significant effect for discrimination (Table 4) and new variable DS were included in ROC curve to analyze specificity and sensitivity. The results are shown in Figure 1 and Table 5.
Figure 1

ROC curve of risk factors (A–L).

Table 5

Area Under the ROC Curves of Risk Factors

VariableAUCSEP95%CI
Taking DKD as the predictive dependent variable
Gender0.5460.0180.011**0.511–0.580
DP0.5640.0170.000**0.530–0.598
GLU0.6810.0170.0000.648–0.714
Cys-C0.0520.0070.000**0.039–0.065
eGFR0.9440.0070.000**0.930–0.959
TVU0.8110.0180.000**0.777–0.846
TCHO0.7240.0160.000**0.693–0.755
FA0.7370.0180.000**0.703–0.772
VB120.6590.0190.000**0.622–0.696
CK0.6510.0160.000**0.619–0.684
CK–Mb0.2900.0200.000**0.251–0.328
DS0.9650.0050.000**0.955–0.976
Taking CKD as the predictive dependent variable
Cys-C0.9480.007*0.000**0.935–0.961
CK–Mb0.7100.020*0.000**0.672–0.749

Notes: **P<0.001; *P<0.05.

Area Under the ROC Curves of Risk Factors Notes: **P<0.001; *P<0.05. ROC curve of risk factors (A–L). The area under the curve (AUC) of indicator Gender, DP, GLU, eGFR, TVU, TCHO, FA, VB12 and CK respectively equals 0.546, 0.564, 0.743, 0.944, 0.811, 0.724, 0.737, 0.659, and 0.651, while eGFR had best efficacy for its AUC is approaching 1. However, the AUC of indicator Cys-C, and CK–Mb only equals 0.025 and 0.290. Thus, the predictive dependent variable was changed from DKD to CKD then the above analysis was repeated. Cys-C and CK–Mb showed positive test efficiency for CKD for their area under curve was 0.948, 0.710 (Figure 1D and K, Table 3). Indicator Cys-C had very good efficacy for CKD. For the DS, the AUC equals 0.965, indicating that this prediction model had the highest efficacy among all variables.

Discussion

In this study, all study subjects were divided into CKD group or DKD group, after comparing the differences of indicator levels between the two groups, relative statistically significant risk factors were also explored to indicate the occurrence of DKD compared to CKD. Then the stepwise discriminant analysis method was used to establish a new variable—DS to predict the occurrence of DKD. Finally, the test efficiency of each of the valuable indicators and the new variable DS was analyzed by drawing the ROC curve, providing basic data and theoretical support for the clinical application of DKD diagnosis. The final result showed that female patients were more likely to develop DN than male patients, with OR=2.438. Moreover, no matter in all the study subjects, or in the CKD group and DN group, the proportion of women was higher than that of men, suggesting that women are more susceptible to kidney disease. Most previous studies have shown that women are a risk factor for CKD and DKD, and even women with diabetes have a greater prevalence of DKD compared to men.31,32 Besides, the high prevalence of diseases among women from this study also suggested that women may not pay attention to their health, while kidney disease is accompanied by a large number of secondary complications and poor prognosis, thus, we should focus more on diagnosis of female CKD and DKD in time. Gender was also used as one of the 11 discriminant variables with statistical significance between the two groups for the establishment of a new variable DS, with the corresponding model had high test efficiency for disease discrimination. More DKD patients were apparently to have an abnormal BMI value (Table 1), even if this factor did not show positive relationship towards DKD after multivariate logistic regression— indicating that doctors also should pay more attention to their diet, hidden obesity and dietary control. The blood pressure values of both groups were close to or exceeded the upper limit of blood pressure, but there were very few cases of extreme hypertension. The SP and DP level of DKD patients were higher than those of CKD patients, and the logistic regression results also suggested that high DP may be a risk factor—the risk to suffer from DKD of people with high DP was 1.746 times that of normal population. Fasting blood GLU as an obvious characteristic indicator of DKD, was consistent with the risk of patients with higher GLU more easily to suffer from DKD (OR=3.404) in this study. And it was also used as one of the 11 indicators establishing DS score and played a role in the prediction of DKD. eGFR, as one of the most common indicators for renal function, has a very special significance in this study. First of all, the eGFR level both of CKD and DKD patients was lower than the normal value. By contrast, patients with DKD have a relatively small reduction in eGFR. Because there was no DKD patient classified into the normal group of eGFR level, we directly included eGFR as a continuous variable into the multivariate regression model. The results showed that based on CKD, the eGFR level was a relative risk factor for DKD (OR=1.107), that is, for every 1 mL/min further to the level of CKD patients, which means 1 mL/min closer to normal value, the risk of DKD could be relatively increased by 0.107. However, since both diseases had abnormal eGFR, it may be inferred that excessive reduction in eGFR was a characteristic manifestation of CKD. To a certain extent, the increase of eGFR (less than normal value) may increase the prevalence of DKD. eGFR had also contained in DS score, suggesting a significant effect for discriminating DKD from CKD. TVU of most subjects was in the normal range, the abnormality of TVU (less or more) in the results of multivariate regression analysis was more directed to the occurrence of DKD, OR=14.030. After considering the TVU value of each subject, although the results of stepwise discriminant analysis also suggest that there existed a significant difference between the two groups, it had little effect on the discriminant score. Therefore, the OR value of regression analysis only had a limited reference value. TCHO of CKD patients were basically normal, while DKD patients showed a significant difference to it. After multivariate logistic regression analysis, the risk of suffering from DKD in people with abnormally elevated levels of TCHO was 3.004 times that of the normal population. Elevated total cholesterol can be commonly seen in nephrotic syndrome and diabetes. The results of our study may suggest that TCHO could be a more meaningful indicator for DKD, which echoes the results of using TCHO in DS scores. Most of subjects showed no deficiency of VB12, however, after classifying them into normal and abnormal level groups, the low level of VB12 was analyzed to be a protective factor for DKD, in other words, deficiency of VB12 may be happened in CKD patients more easily. Although Cys-C, FA, CK and CK–Mb did not show positive results in a logistic regression model, they had been included into DS score establishment and showed very significant effect. This may be due to the value of each subject not being used in the regression model of categorical variables, the hazard risk analysis of Cys-C, FA, CK and CK–Mb for DKD or CKD was underestimated. Based on the results of stepwise discriminant analysis, the DS score was established and its test efficiency is higher than that of any 11 variable which is statistically significant between the two groups. Thus, discriminant formula used for CKD and DN identification is more intuitive than accurate (Table 4). After completing the detection of DP, fasting blood GLU, Cys-C, eGFR, TVU, TCHO, FA, VB12, CK, and CK–Mb, doctor’s diagnosis can be assisted by substituting the indicator values into the discriminant. If the value of DKD calculated by the above formula is higher, this patient may be more likely to suffer from DKD than CKD, specifically.

Conclusion

Female, higher SP, fasting blood GLU and TCHO level were seen to be more indicative for DKD, while lower eGFR level and VB12 deficiency were more likely to point to CKD. Doctors can refer to the discriminant formula to assist in the differential diagnosis of the two diseases after completing the detection of DP, fasting blood GLU, Cys-C, eGFR, TVU, TCHO, FA, VB12, CK, and CK–Mb.
  27 in total

1.  The prognostic role of different renal function phenotypes in patients with acute heart failure.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Pierpaolo Pellicori; Eufemia Incampo; Cristina Di Tommaso; Roberto Favilli; Isabella Evangelista; Ranuccio Nuti; Jeffrey M Testani
Journal:  Int J Cardiol       Date:  2018-11-23       Impact factor: 4.164

2.  Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Authors:  Andrew G Bostom; Myra A Carpenter; John W Kusek; Andrew S Levey; Lawrence Hunsicker; Marc A Pfeffer; Jacob Selhub; Paul F Jacques; Edward Cole; Lisa Gravens-Mueller; Andrew A House; Clifton Kew; Joyce L McKenney; Alvaro Pacheco-Silva; Todd Pesavento; John Pirsch; Stephen Smith; Scott Solomon; Matthew Weir
Journal:  Circulation       Date:  2011-04-11       Impact factor: 29.690

Review 3.  Folate, vitamin B12 and vitamin B6 and one carbon metabolism.

Authors:  J Selhub
Journal:  J Nutr Health Aging       Date:  2002       Impact factor: 4.075

4.  Risk factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: the pathways study.

Authors:  Margaret K Yu; Courtney Rees Lyles; Luis A Bent-Shaw; Bessie A Young
Journal:  Am J Nephrol       Date:  2012-09-04       Impact factor: 3.754

5.  A Differential Diagnosis Model For Diabetic Nephropathy And Non-Diabetic Renal Disease In Patients With Type 2 Diabetes Complicated With Chronic Kidney Disease.

Authors:  Zhenhua Yang; Luhuai Feng; Yu Huang; Ning Xia
Journal:  Diabetes Metab Syndr Obes       Date:  2019-09-30       Impact factor: 3.168

Review 6.  Role of homocysteine in the development of cardiovascular disease.

Authors:  Paul Ganguly; Sreyoshi Fatima Alam
Journal:  Nutr J       Date:  2015-01-10       Impact factor: 3.271

7.  Haematological profile of chronic kidney disease in a mixed-ancestry South African population: a cross-sectional study.

Authors:  Cindy George; Tandi E Matsha; Rajiv T Erasmus; Andre P Kengne
Journal:  BMJ Open       Date:  2018-11-03       Impact factor: 2.692

8.  Analysis of chronic kidney disease staging with different estimated glomerular filtration rate equations in Chinese centenarians.

Authors:  Qiu-Xia Han; Dong Zhang; Ya-Li Zhao; Liang Liu; Jing Li; Fu Zhang; Fu-Xin Luan; Jia-Yu Duan; Zhang-Suo Liu; Guang-Yan Cai; Xiang-Mei Chen; Han-Yu Zhu
Journal:  Chin Med J (Engl)       Date:  2019-03-05       Impact factor: 2.628

Review 9.  Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?

Authors:  Giuseppe Cianciolo; Antonio De Pascalis; Luca Di Lullo; Claudio Ronco; Chiara Zannini; Gaetano La Manna
Journal:  Cardiorenal Med       Date:  2017-06-21       Impact factor: 2.041

10.  Effect of hydrocortisone on the 28-day mortality of patients with septic acute kidney injury.

Authors:  Pan Ying; Chenguang Yang; Xianlong Wu; Qiqi Cai; Wenwei Xin
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.